Small Cap Feast
Small Cap Feast – 01 July 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 893
Total number of AIM Companies trading: 813*
* As at 01 June 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 01 June 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 163*
Total number of Standard List Companies trading: 141*
* As at 01 June 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Clean Invest Africa (NEX:CIA)—readmission and all share RTO of CoalTech (South Africa) engaged in agglomerating coal fines into coal pellets through the commercialisation o f its proprietary binding technology. Due early Aug.
Main Market (Premium)
ReAssure Group plc – The Group is a leading closed book life insurance consolidator in the United Kingdom with 4.3m policies, £68.7 billion of assets under administration on a Post-L&G Illustrative Basis. It is considering a premium listing segment of the main market.
Main Market (Specialist Funds)
Voyager AIR The Company will focus on the acquisition, leasing and management of primarily widebody aircraft, with asset management services to be provided by Amedeo Limited he IPO will comprise a Placing and Offer for Subscription of Shares to raise up to approximately US$200m·
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. TBC
Uniphar, a diversified healthcare services business with a workforce of over 2,000, is looking to join AIM. Raise TBC, expected mid-July 2019
Rumours & Speculation
Neptune Surf Technology plc*, a vertically integrated lifestyle accessory group focused on the surf market, designing its own high-performance wetsuits and surfing hardware and distributing these together with third party brands globally with key markets being Europe, Australia and USA and Brazil, is looking to join AIM and ‘is planning an £11m float’ according to The Sunday Telegraph.
Kromek (KMK.L) 25p £83.56m
Kromek, a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announced that it has been awarded three contracts, in the UK, US and Europe, for its D3S platform for nuclear radiation detection.
These new awards consist of:
a £1.1m contract from a UK government-related company to provide D3S-related technologies;
a $389k contract from the US government’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to provide D3S-related customisation for military operational transition, which will leverage the DARPA SIGMA Program sensor and technology; and
a €180k contract from the European Commission’s Directorate-General for Migration and Home Affairs for the D3S-ID and drone-mounted D3S for wide-area monitoring.
RA International (RAI.L) 50p £84.18m
RA International, a leading provider of services to remote locations in Africa and the Middle East, has been awarded a new contract by a global humanitarian organisation to supply and install modified shipping containers as accommodation and offices in an East African country.
RA’s services are required to upgrade the security of existing accommodation and office units from prefab units to steel containers with overhead protection. This contract award follows smaller similar projects undertaken for the same client.
The contract will run for one year, commencing immediately, and is valued at $7.8m.
Eckoh (ECK.L) 49p £119.27m
Eckoh, the global provider of secure payment products and customer contact solutions, announced it has secured a three-year contract to provide Coral (the contact centre agent desktop product), to a US Fortune 100 telecommunications company. This is a significant extension to an existing client relationship.
Eckoh has an exclusive contract to sell Coral, and over the last two years the telecommunications company, who is one of Eckoh’s largest clients, has deployed the market-leading desktop into parts of its contact centre estate, as well as other Eckoh services. This new contract represents the next phase of their process to implement Coral, and their commitment to three years of support suggests Coral is their long-term desktop of choice.
The contract is worth a minimum of $3.8m to Eckoh, comprising $2.1m in licences and $1.7m for maintenance and support over the three-year period.
Gfinity (GFIN.L) 5.3p £18.3m
Gfinity, a world-leading esports business, announced a trading update for the year ended 30 June 2019.
The Company leadership has refocused the business on a Strategic Client Management model which has delivered strong revenue and EBITDA growth. This encouraging performance has been driven by:
Growth in strategic partnerships, highlighting Gfinity’s position as one of the world leaders in the esports and competitive gaming sector:
New strategic partners, further demonstrating Gfinity’s growing reputation as a provider of unique esports solutions:
GAN (GAN.L) 74p £59.65m
GAN, an award-winning developer and supplier of enterprise-level B2B Internet gambling software and services in the United States and Europe, provided an update on trading for the second calendar quarter period ending June 30, 2019.
In the second calendar quarter period ending June 30, 2019 trading was ahead of expectations with the seasonal decline in Internet gambling volumes typically experienced during the early months of Summer mitigated by various factors including:
High demand in Q2 for Internet sports betting on both basketball and baseball in New Jersey, despite the cessation in Q1 of the primary U.S. sports season relating to American Football; and
Higher than expected casino cross-selling from Internet sports bettors into internet casino gaming in New Jersey during the Q2 period.
The outlook for 2019 continues to remain highly positive for GAN. The Company now expects to see high double-digit revenue growth for the full year 2019.
OKYO Pharma (OKYO.L) 2.05p £11.21m
OKYO Pharma announced its final audited results for the year ended 31 March 2019.
Summary of OKYO-0101 studies during the last year
Increase in corneal permeability due to dry eye was reduced significantly by OKYO-0101 compared to vehicle group
Potency of OKYO-0101 in reducing corneal permeability was comparable to cyclosporine, an active ingredient of Restasis® (Allergan)
OKYO‑0101 normalised the dry eye induced loss of goblet cell density
OKYO-0101 reduced the dry eye induced-enhancement of CD4+ T-cells, which are known biomarkers of inflammation
Rabbit Ocular tolerance test using OKYO-0101 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs of local irritation
Clinical ophthalmic exam of rabbit eyes after topical application of OKYO-0101 for 4 days (twice daily) showed no discharge, cloudiness, vascularization, edema, inflammation or retinal hemorrhage
Total comprehensive loss of £3.8m (31 March 2018: £20.2m)
Cash balance at 31 March 2019 of £0.5m (31 March 2018: £2m).
Basic and diluted loss per share decreased to 0.01p per share (31 March 2018: 0.05p)
Proteome Sciences (PRM.L) 3.1p £9.15m
Following the announcement of TMTpro 16plex isobaric mass tags during the American Society for Mass Spectrometry (ASMS) meeting in Atlanta in June, Proteome Sciences is launching upgrades to its core proteomic services (SysQuant®, TMTcalibrator™ and Plasma Super Depletion) with increased multiplexing. Testing has shown that these new reagents perform equivalently to the current 11-plex TMT® in terms of the numbers of quantified peptides and proteins, whilst providing a 50% increase in the number of samples that can be analysed in a single experiment.
TMTpro is a completely re-designed set of isobaric mass tags developed and patented by Proteome Sciences, with multiple benefits over the previous TMT reagents. As well as offering five extra channels, the new chemistry also provides a 9-plex set of single-Dalton resolved tags for use with TMT complement ion quantification. In addition, the reporter ion is more readily fragmented and offers gains in signal-to-noise both in MS2 and MS3 analyses.
Adding TMTpro 16-plex reagents to standard service workflows will provide significant benefits to clients in both the size and speed of biomarker discovery projects.
LightwaveRF (LWRF.L) 7.5p £6.69m
LightwaveRF, the leading smart home solutions provider, announced that it has signed an agreement with Google to jointly market its Lightwave compatible smart speakers, making Lightwave the first installed Smart Lighting manufacturer in the UK to offer the convenience of voice-controlled lighting in one starter kit purchase.
The Google Mini and Google Nest Hub, supplied by Google, are being made available for customers to purchase at an attractive bundle price from Lightwave directly on www.lightwaverf.com or from a selection of Lightwave authorised retailers and stockists, including AO.com.
The starter kit bundles offer launched in Germany on the evening of 28 June 2019, via the dedicated Smart Home online retailer, Tink, whilst the UK is scheduled to follow later this month and other European markets thereafter.
Lightwave will also work closely with Google to educate customers on the benefits of the voice-activated Google Assistant for managing their home. Together they will engage in a range of initiatives to demonstrate Lightwave and Google products working together in-store and online.
Randall & Quilter (RQIH.L) 177.5p £347.7m
Randall & Quilter Investment announced that its wholly owned subsidiary, Randall & Quilter II Holdings Limited, has signed an agreement to acquire, subject to regulatory approval from the Bermuda Monetary Authority, the entire issued share capital of Sandell Holdings Limited along with its 100% owned subsidiary Sandell Re Limited which was incorporated in Bermuda in 2014, and was licensed as a Class 3A segregated account company by the BMA in Feb 2015, to write all classes of general business insurance and reinsurance.
The residual liabilities comprise primarily of contractor’s liability exposures arising in the US. SRL had net technical reserves of $48.3m as at 31 Dec 2018. The cash consideration payable at closing by R&Q is $25m with further amounts payable subject to certain conditions being met. This represents a discount to the Company’s net assets which, at 31 Dec 2018, were $40.8m. In the year to 31 Dec 2018 SHL recorded a loss of $2.7m.
Walker Greenbank (WGB.L) 81.5p £57.85m
Walker Greenbank, the luxury interior furnishings group, announced that it has entered into a distribution agreement with Kravet Inc., the premier US home furnishings resource available exclusively to the trade, for the distribution of its Clarke & Clarke and Studio G brands in the US.
Kravet Inc., a fifth generation family business founded in 1918, owns and distributes Kravet, Lee Jofa, Groundworks, Brunschwig & Fils and the UK’s GP & J Baker brands as well as distributing a series of other high market brands – all specialising in style, luxury and exceptional design.
Walker Greenbank has a track record of working with Kravet Inc. through the Company’s manufacturing operations, which print wallpapers and fabrics for certain Kravet Inc. brands.
Kravet Inc. replaces Robert Allen Duralee Group (RADG), the Company’s previous US distributor of the Clarke & Clarke and Studio G brands.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.